Original Article
Subject Category: Acquired and Multigenic Disease
Molecular Therapy (2008); doi:10.1038/mt.2008.165
Gene-eluting Stents: Adenovirus-mediated Delivery of eNOS to the Blood Vessel Wall Accelerates Re-endothelialization and Inhibits Restenosis
Faisal Sharif1,2, Sean O Hynes1, Ronan Cooney1, Linda Howard1, Jill McMahon1, Kieran Daly2, James Crowley2, Frank Barry1 and Timothy O'Brien1,2,3
- 1Regenerative Medicine Institute, National Centre for Biomedical Science Engineering, National University of Ireland, Galway, Ireland
- 2Department of Cardiology, University College Hospital Galway, National University of Ireland, Galway, Ireland
- 3Department of Medicine, University College Hospital Galway, National University of Ireland, Galway, Ireland
Correspondence: Timothy O'Brien, Department of Medicine, Clinical Sciences Institute, University College Hospital, Galway, Ireland. E-mail: timothy.obrien@nuigalway.ie
Received 11 May 2007; Accepted 2 July 2008; Published online 19 August 2008.
Abstract
Drug-eluting stents for coronary artery disease results in inhibition of smooth muscle cell (SMC) and endothelial cells which may increase the risk of stent thrombosis. In this study, we attempted to enhance re-endothelialization of deployed stents while simultaneously inhibiting intimal hyperplasia by overexpression of endothelial nitric oxide synthase (eNOS) delivery in the vasculature using an adenovirus gene–eluting stent. Re-endothelialization was significantly greater in vessels obtained from normocholesterolemic animals at day 14 (85.34%
7.38 versus 62.66%
10.49; P < 0.05) and day 28 (91.1%
10 versus 63.1%
22; P < 0.05) and hypercholesterolemic animals (96.97%
3.2 versus 28.33%
38.76; P < 0.05) at day 28 with AdeNOS-eluting stents. At day 28, there was a significant increase in the lumen size [AdeNOS 2.73 mm2
1.18, Ad
Gal 0.98 mm2
0.98, phosphorylcholine (PC) 1.87 mm2
1.18; P < 0.05], and a significant reduction in neointimal formation (AdeNOS 2.32 mm2
1.13, Ad
Gal 3.73 mm2
0.95, PC 3.2 mm2
0.94; P < 0.05), and percent restenosis (AdeNOS 45.23
20.81, Ad
Gal 79.6
20.31, PC 70.16
22.2; P < 0.05) in AdeNOS-stented vessels in comparison with controls from hypercholesterolemic animals, assessed by morphometry and quantitative coronary angiography (AdeNOS 15.95%
7.63, Ad
Gal 56.9%
38.6, PC 58
34.6; P < 0.05). Stent-based delivery of AdeNOS results in enhanced endothelial regeneration and reduction in neointimal formation as compared with controls. This seems to be a promising treatment strategy for preventing in-stent restenosis (ISR) while simultaneously reducing the risk of stent thrombosis.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Gene-eluting Stents: Adenovirus-mediated Delivery of eNOS to the Blood Vessel Wall Accelerates Re-endothelialization and Inhibits RestenosisMolecular Therapy Original Article
Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeysGene Therapy Research Article
Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stentGene Therapy Research Article
Targeting Vascular Injury Using Hantavirus-Pseudotyped Lentiviral VectorsMolecular Therapy Original Article
See all 30 matches for Research
